|

Ocrelizumab Clinical Trials

7 actively recruiting trials across 3 locations

▼ -2 trials since June 2026

Also known as: OCREVUS®, Ocrevus, RO4964913, RO4964913, Ocrevus, RO4964913; Ocrevus +1 more

Pipeline

Phase 2: 1Phase 3: 3Phase 4: 2

Top Sponsors

  • Hoffmann-La Roche3
  • Novartis Pharmaceuticals1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Johns Hopkins University1
  • Biocad1

Indications

  • Multiple Sclerosis7
  • Relapsing Multiple Sclerosis1
  • Relapsing-remitting Multiple Sclerosis (RRMS)1
  • Progressive Multiple Sclerosis1

Other4 trials

A Study of the Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis
Phase 3
A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of RO7268489 as Add-on Therapy to Ocrelizumab, in Participants With Progressive Forms of Multiple Sclerosis (MS)
Phase 2
A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)
An Extension Study to Assess Impact of Multiple Sclerosis (MS) on Physical Function and Provide Continued Ocrelizumab Treatment
Phase 3

Scottsdale, Arizona1 trial

Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.

Perseverance Research Center

Phase 3

New Haven, Connecticut1 trial

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis

Yale School of Medicine

Phase 4

Baltimore, Maryland1 trial

Study of Ublituximab for Ocrelizumab Wearing-Off in Multiple Sclerosis

Johns Hopkins University

Phase 4

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.